Orchestra BioMed Hldgs Analyst Ratings
Orchestra BioMed Hldgs Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/11/2023 | 229.49% | Chardan Capital | → $20 | Reiterates | Buy → Buy |
| 08/09/2023 | 229.49% | Chardan Capital | → $20 | Reiterates | Buy → Buy |
| 05/15/2023 | 229.49% | Chardan Capital | → $20 | Reiterates | Buy → Buy |
| 02/24/2023 | 147.12% | Piper Sandler | → $15 | Initiates Coverage On | → Overweight |
| 02/07/2023 | 229.49% | Chardan Capital | → $20 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 2023年08月11日 | 229.49% | 查爾丹資本 | →$20 | 重申 | 購買→購買 |
| 08/09/2023 | 229.49% | 查爾丹資本 | →$20 | 重申 | 購買→購買 |
| 2023年05月15日 | 229.49% | 查爾丹資本 | →$20 | 重申 | 購買→購買 |
| 02/24/2023 | 147.12% | 派珀·桑德勒 | →$15 | 開始承保 | →超重 |
| 02/07/2023 | 229.49% | 查爾丹資本 | →$20 | 開始承保 | →購買 |
What is the target price for Orchestra BioMed Hldgs (OBIO)?
樂團BioMed Hldgs(OBIO)的目標價格是多少？
The latest price target for Orchestra BioMed Hldgs (NASDAQ: OBIO) was reported by Chardan Capital on August 11, 2023. The analyst firm set a price target for $20.00 expecting OBIO to rise to within 12 months (a possible 229.49% upside). 5 analyst firms have reported ratings in the last year.
查爾丹資本於2023年8月11日報道了樂團BioMed Hldgs(納斯達克：OBIO)的最新目標價。這家分析公司將目標價定為20美元，預計OBIO將在12個月內升至(可能上漲229.49%)。去年有5家分析公司公佈了評級。
What is the most recent analyst rating for Orchestra BioMed Hldgs (OBIO)?
樂團BioMed Hldgs(OBIO)的最新分析師評級是多少？
The latest analyst rating for Orchestra BioMed Hldgs (NASDAQ: OBIO) was provided by Chardan Capital, and Orchestra BioMed Hldgs reiterated their buy rating.
納斯達克(Sequoia Capital：OBIO)對樂團BioMed Hldgs的最新分析師評級由查爾丹資本提供，樂團BioMed Hldgs重申其買入評級。
When is the next analyst rating going to be posted or updated for Orchestra BioMed Hldgs (OBIO)?
樂團BioMed Hldgs(OBIO)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Orchestra BioMed Hldgs, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Orchestra BioMed Hldgs was filed on August 11, 2023 so you should expect the next rating to be made available sometime around August 11, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公開財務報表，與Orchestra BioMed Hldgs的高管和客戶交談，以及收聽收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。對交響樂團BioMed Hldgs的上一次評級是在2023年8月11日提交的，所以你應該預計下一次評級將在2024年8月11日左右提供。
Is the Analyst Rating Orchestra BioMed Hldgs (OBIO) correct?
分析師對交響樂團BioMed Hldgs(OBIO)的評級正確嗎？
While ratings are subjective and will change, the latest Orchestra BioMed Hldgs (OBIO) rating was a reiterated with a price target of $0.00 to $20.00. The current price Orchestra BioMed Hldgs (OBIO) is trading at is $6.07, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的交響樂團BioMed Hldgs(OBIO)評級被重申，目標價在0.00美元至20.00美元之間。目前樂團BioMed Hldgs(OBIO)的交易價格為6.07美元，在分析師的預測範圍內。
譯文內容由第三人軟體翻譯。